Amgen Inc.
Pembelian

🔬💊 Amgen Innovations & Strategic Moves 🚀

152
🌟 Lumakras Breakthrough:
Amgen (AMGN) pioneers cancer treatment with Lumakras, the first medication targeting a mutation found in approximately 13% of lung cancer patients.

💰 Strategic Acquisition:
Amgen acquires Horizon Therapeutics for a substantial $28 billion in cash.
Incorporates Tepezza, an FDA-approved medicine for thyroid eye disease, into Amgen's product portfolio.

📈 Market Outlook:
Bullish stance on AMGN suggests support levels above $260.00-$265.00.
Anticipated upside target in the range of $360.00-$365.00.

Exciting developments in biotech and strategic expansion for Amgen! 🌐💉

#AmgenInnovation #Biotech #StockMarket 📰📊

Pernyataan Penyangkalan

Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.